Attention-Deficit/Hyperactivity Disorder | Treatment Algorithms: Claims Data Analysis | Adult | US | 2021

Attention-deficit/hyperactivity disorder (ADHD) is a common childhood disorder that can persist into adulthood, although diagnosis and treatment initiation can occur at any age. Data suggest that diagnosis and drug-treatment rates among adults have historically lagged behind those of pediatric patients, but growing awareness of ADHD as an adult disorder—influenced, in part, by updated diagnostic criteria—has, in recent years, fueled greater industry focus on treating adult patients. Psychostimulants, nonstimulants, and amphetamines are key therapies for this population. This study uses national patient-level claims data to determine the prescribing patterns of drugs for adult patients with ADHD.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult ADHD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult ADHD patients?
  • How have Takeda’s Mydayis, Ironshore’s Jornay PM, and Adlon’s Adhansia XR been integrated into the treatment algorithm? What is their source of business?
  • What percentage of adult ADHD patients receive drug therapy within a month of diagnosis? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of adult ADHD patients receive monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Takeda, Arbor Pharmaceuticals, Tris Pharma, Adlon Therapeutics, Ironshore Pharmaceuticals

Key drugs: Mydayis, Vyvanse, Jornay PM, Adhansia XR


The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Login to access report